Octreotide-LAR-associated erythema multiforme in an acromegalic subject: case report.
Long-acting somatostatin analogs are often used for treating acromegaly, either as adjuvant to surgery or radiotherapy or, more recently, as a primary therapeutic option. These drugs seem to be reasonably safe, but new adverse effects not yet described may occur during the use of the relatively new long-acting formulations. In this case report, we describe a severe cutaneous reaction (erythema multiforme) in a patient treated with long-acting release (LAR) octreotide, and also discuss the need of previous "testing" with short subcutaneous preparation of octreotide.
Cavalin
Leda R
LR
Department of Clinical Medicine, Universidade Estadual de Londrina, Brazil. ledarc@pop.com.br
Oliveira
Maria L de
ML
Diehl
Leandro A
LA
D000172:Acromegaly / Q000188:drug therapy*; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects*; D004892:Erythema Multiforme / Q000139:chemically induced*; D006801:Humans; D015282:Octreotide / Q000009:adverse effects*; D010456:Peptides, Cyclic / Q000009:adverse effects; D013004:Somatostatin / Q000009:adverse effects / Q000031:analogs & derivatives
D018931:Antineoplastic Agents, Hormonal; D010456:Peptides, Cyclic; C060347:lanreotide; D013004:Somatostatin; D015282:Octreotide